Rating Change
Barclays reiterated its Overweight rating on Ascendis Pharma A/S (NASDAQ:ASND) on August 14, 2026.
reiterateNASDAQ:ASND
Barclays Reiterates Overweight Rating on Ascendis Pharma A/S (ASND)
Barclays reiterated its Overweight rating on Ascendis Pharma A/S (NASDAQ:ASND) on August 14, 2026.
At publication ·
What changed
Ascendis Pharma A/S (NASDAQ:ASND) · reiterate
- Firm
- Barclays
- Rating
- Overweight to Overweight
- Price at event
- $248.50
- Market capitalization
- $14.3B
At a glance
Key takeaways
- Barclays reiterated an Overweight rating on Ascendis Pharma (ASND) on August 14, 2026, with the stock trading at $248.50 and a market capitalization of $14.3 billion.
Market Context
Ascendis Pharma A/S operates in the Healthcare sector. The stock currently trades at $248.50 with a market capitalization of $14.3B.
Analyst coverage from Barclays provides professional research and price targets that many institutional investors reference when making allocation decisions. The consensus of analyst opinions — along with the range of price targets — helps frame market expectations for Ascendis Pharma A/S.
Analyst ratings and price targets are one input among many for investment decisions. Historical studies show that consensus analyst recommendations have mixed predictive power on their own, but significant changes in consensus — such as multiple upgrades or downgrades in a short period — can be more meaningful signals.
Recent Analyst Activity for Ascendis Pharma A/S
Among the 10 most recent ratings: 10 Buy, 0 Hold, 0 Sell.
| Date | Firm | Rating | Price Target |
|---|---|---|---|
| Aug 14, 2026 | RBC Capital | Outperform | N/A |
| Aug 14, 2026 | TD Cowen | Buy | N/A |
| Aug 14, 2026 | Barclays | Overweight | N/A |
| Jul 23, 2026 | Morgan Stanley | Overweight | N/A |
| Jul 07, 2026 | RBC Capital | Outperform | N/A |
Related Tools: Analyst Ratings Dashboard | View ASND Stock Page
Frequently Asked Questions
What does the Overweight rating mean for ASND?
A rating of Overweight from Barclays reflects the analyst's outlook on Ascendis Pharma A/S (NASDAQ:ASND). Analyst ratings are one factor investors consider alongside earnings, valuation, and sector trends.
Where can I find more analyst ratings?
Browse recent upgrades and downgrades on our Analyst Ratings Dashboard or the ASND forecast page.